Alabama Opens First Medical Cannabis Dispensary After Five-Year Wait Amid Audit Scrutiny

Alabama is set to witness a historic milestone as the state’s first licensed medical cannabis dispensary, Callie’s Apothecary in Montgomery, prepares to open its doors on May 4. This launch comes five years after the Alabama legislature legalized medical marijuana in 2021, marking a significant turning point for patients seeking legal access to cannabis-based treatments. The Alabama Medical Cannabis Commission (AMCC) announced the long-awaited opening at its April 9 meeting, underscoring the state’s cautious and methodical approach to rolling out its medical cannabis program

Dr. Sam Blakemore, chairman of the AMCC, praised Callie’s Apothecary for its welcoming atmosphere, likening it to a traditional pharmacy. "Callie’s Apothecary put me at home," Blakemore said. AMCC Director John McMillan highlighted the robust security protocols in place, stating, "A patient will not be able to even enter the door unless a picture is taken of their medical cannabis card and relayed through the system. Cameras everywhere, lights everywhere, locks everywhere." These measures reflect Alabama’s emphasis on security and regulatory compliance as it launches its inaugural dispensary

Callie’s is the first of nine dispensaries operated by three companies expected to open by this summer, while a fourth license remains tied up in litigation. Despite ongoing legal disputes, the commission confirmed that the May rollout will proceed as planned. According to the commission’s projections, all 12 dispensary locations could be operational by the fourth quarter of 2026. As of the latest meeting, more than 40 physicians are authorized to prescribe medical cannabis, and 66 patient cards have been issued—a figure expected to climb as dispensaries begin serving patients

The program’s debut is not without controversy. A recent state audit, as reported by MJBizDaily, found several operational failings within the AMCC, including violations of open meetings laws, overpayment of $204,000 to an external law firm, poor record-keeping, and an inadequate fee structure. These findings mirror complaints from unsuccessful license applicants and have contributed to years of delays, with legal battles forcing the commission to redo licensing rounds and pushing the program’s launch from its original 2024 target to 2026. The audit’s timing—emerging just before the first dispensary opens—has intensified scrutiny of the commission’s governance

State law allows for a tightly regulated market, with a cap of five vertically integrated businesses (each operating up to five retail locations), 12 cultivators, four processors, and four dispensary-only permits. Currently, four dispensary companies, nine cultivators, and four processors have been licensed. Ray French, CEO of Specialty Medical Products, expressed optimism despite the ongoing litigation: "At the end of the day, getting patients medicine is what it’s all about. We’re very encouraged by the proceedings with the independent licenses and we’re hopeful that at the end we’ll also have an opportunity to participate."

From the OG Lab newsroom perspective, Alabama’s delayed but imminent launch underscores the challenges faced by states transitioning from legalization to implementation. The state’s experience highlights the importance of robust governance and transparent processes in building trust and ensuring timely patient access. As Alabama finally opens its doors to medical cannabis patients, the industry will be watching closely to see whether the program delivers on its promise or continues to struggle under regulatory and legal hurdles